TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Hansa Biopharma AB ( (SE:HNSA) ) has issued an update.
Hansa Biopharma AB announced a virtual event featuring transplant experts to discuss the Phase 3 results of their imlifidase treatment for highly sensitized kidney transplant patients. The event aims to provide insights into the clinical relevance of these results and their potential impact on the standard of care for transplant patients, highlighting the company’s commitment to addressing the needs of this challenging patient group.
The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK132.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company focused on developing and commercializing innovative treatments for patients with rare immunological conditions.
Average Trading Volume: 678,042
Technical Sentiment Signal: Sell
Current Market Cap: SEK2.71B
For a thorough assessment of HNSA stock, go to TipRanks’ Stock Analysis page.